One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
LAUSANNE, Switzerland, Nov. 14, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative.
Guardant Health (GH) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
Clinical trial of AX-05 showed drug reduces patient agitation Continue reading...
Top Ranked Momentum Stocks to Buy for January 30th
CHF 32 Million in Milestone Revenues Multiple Upcoming Catalysts Execution Across Clinical and Preclinical Neurodegenerative Development Pipeline LAUSANNE, Switzerland,.
Press Release - Cindy Nidene Roos (39), a police Sergeant, was on Friday, 22 May 2020, released on R1000-00 bail upon appearance in the Rustenburg Magistrate's Court for theft and defeating the ends of justice. She will reappear on Monday, 31 August 2020.
LAUSANNE, Switzerland, May 15, 2020 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative.
Seven presentations by AC Immune and its partners at AAT-AD/PD™ New data on early-stage TDP-43 and alpha-synuclein therapeutic and diagnostic candidates A lead.
AC Immune (ACIU) delivered earnings and revenue surprises of 47.06% and 24.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company, today announced that it will receive a second milestone payment of CHF 10 million from Eli Lilly and Company on or before March 31, 2020 related to development progress in the small molecule Morphomer™ Tau aggregation inhibitor program. The multi-year collaboration agreement between Lilly and AC Immune was originally announced in December 2018 and focuses on the broad development of Morphomer™ Tau aggregation inhibitors for Alzheimer’s disease (AD) and other neurodegenerative diseases.
Companies in the news are: HAS, PCG, WTRH, ACIU
LAUSANNE, Switzerland, March 05, 2020 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, announced today that four new data presentations.
On track to meet the five clinical milestones expected in 2020 with no modifying guidance as a result of Covid-19Ongoing strong financial position with CHF 277.9 million in.
As you might know, AC Immune SA (NASDAQ:ACIU) just kicked off its latest quarterly results with some very strong...
LAUSANNE, Switzerland, March 20, 2020 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative.
The three officers appeared in court after being arrested this week in connection with the theft of confiscated illicit cigarettes and alcohol in two separate incidents.
Ongoing strong financial position with CHF 288.6 million in cash, ensuring the Company is fully financed through Q1 2024, excluding potential incoming milestonesReceived CHF 110.
Clinical trial of AX-05 showed drug reduces patient agitation Continue reading...
The analysts covering AC Immune SA (NASDAQ:ACIU) delivered a dose of negativity to shareholders today, by making a...
Andrea Pfeifer is the CEO of AC Immune SA (NASDAQ:ACIU). This analysis aims first to contrast CEO compensation with...
Moderna (MRNA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.